The Cochrane Central Register of Controlled Trials reveals that there are currently 72 clinical trials focused on Theranostics and their potential to enhance therapeutic management of various diseases globally.
These trials reflect the growing interest in utilizing Theranostics, which combines therapeutic and molecular imaging diagnostic components, to advance personalized medicine and improve clinical outcomes.
The objective is to improve the existing standards for treating Keratoconus by adopting a more detailed evidence based medicine approach. There is an undying commitment to ensure that their therapeutic management techniques are backed by the furthest possible scientific research and studies, providing patients with the highest level of care and effectiveness.
Regensight is a new eye healthcare company exploiting proprietary Theranostics technology for incision free treatment of visual disorders.